Brief: Reviva Pharmaceuticals Recover-2 Trial Projected To Cost About $60 Million
23/12/2025 13:10
Dec 23 (Reuters) - Reviva Pharmaceuticals Holdings Inc RVPH.O: REVIVA PHARMACEUTICALS: RECOVER-2 TRIAL PROJECTED TO COST ABOUT $60 MILLION REVIVA PHARMACEUTICALS: MAY INITIATE PHASE 3 TRIAL OF BRILAROXAZINE FOR NEGATIVE SYMPTOMS OR BIPOLAR DISORDER IN Q2 2026 REVIVA PHARMACEUTICALS: NEGATIVE SYMPTOMS/BIPOLAR TRIAL IS PROJECTED TO COST ABOUT $30 MILLION Source text: [ID:n0001437749-25-038602] Further company coverage: RVPH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reviva Pharmaceuticals Holdings
See all newsReviva Pharmaceuticals Q1 net loss narrows on lower expenses
Brief: Reviva Pharmaceuticals Holdings Inc - To Be Delisted From Nasdaq Trading Suspended As Of May 14, 2026 - SEC Filing
Brief: Reviva Reports Full Year 2025 Financial Results And Recent Business Highlights
Reviva Pharmaceuticals' 2025 net loss narrows on lower R&D spending
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture